Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist.
about
Acupuncture for treatment of irritable bowel syndromeAcupuncture for treatment of irritable bowel syndromeNew and emerging therapies for the treatment of irritable bowel syndrome: an update for gastroenterologistsDiagnosis and treatment of diarrhea-predominant irritable bowel syndromeFunctional GI disorders: from animal models to drug development.Incidence of ischemic colitis and serious complications of constipation among patients using alosetron: systematic review of clinical trials and post-marketing surveillance data.Pharmacology and clinical experience with alosetron.Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome.Impact of 5-HT3 receptor blockade on colonic haemodynamic responses to ischaemia and reperfusion in the rat.Evaluation of the Birmingham IBS symptom questionnaireA randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating.Sex-Related Differences in Clinical Symptoms, Quality of Life, and Biochemical Factors in Irritable Bowel Syndrome.Fermentable carbohydrates (FODMAPs) exacerbate functional gastrointestinal symptoms in patients with inflammatory bowel disease: a randomised, double-blind, placebo-controlled, cross-over, re-challenge trial.Placebo effect in clinical trial design for irritable bowel syndromeWhich patients improve: characteristics increasing sensitivity to a supportive patient-practitioner relationship.Studying sex and gender differences in pain and analgesia: a consensus report.An Evidence-Based Look at Misconceptions in the Treatment of Patients with IBS-DTherapy of the postinfectious irritable bowel syndrome: an update.Gender-related differences in irritable bowel syndrome: potential mechanisms of sex hormones.Gender Differences in Serotonin Signaling in Patients with Diarrhea-predominant Irritable Bowel SyndromeInsights into the pathophysiology and mechanisms of constipation, irritable bowel syndrome, and diverticulosis in older people.Serotonin: a mediator of the brain-gut connection.Activation of submucosal 5-HT(3) receptors elicits a somatostatin-dependent inhibition of ion secretion in rat colonLubiprostone: evaluation of the newest medication for the treatment of adult women with constipation-predominant irritable bowel syndromeGenetics and pharmacogenetics of aminergic transmitter pathways in functional gastrointestinal disorders.Irritable bowel syndrome: an update on therapeutic modalities.Guidelines on the irritable bowel syndrome: mechanisms and practical management.Alosetron and irritable bowel syndrome.Review article: serotonin receptors and transporters -- roles in normal and abnormal gastrointestinal motility.Sensation and gas dynamics in functional gastrointestinal disorders.Serotonergic modulation of visceral sensation: lower gut.Serotonergic modulating drugs for functional gastrointestinal diseases.Clinical perspectives, mechanisms, diagnosis and management of irritable bowel syndrome.Functional heartburn: the stimulus, the pain, and the brainPharmacological characterization of the 5-HT receptor-mediated contraction in the mouse isolated ileum.The role of experimental models in developing new treatments for irritable bowel syndrome.Review article: visceral hypersensitivity.Stress-induced visceral pain: toward animal models of irritable-bowel syndrome and associated comorbidities.Novel therapies in the treatment of irritable bowel syndrome.A Randomised, Cross-Over, Placebo-Controlled Study of Aloe vera in Patients with Irritable Bowel Syndrome: Effects on Patient Quality of Life.
P2860
Q24244050-51D481E5-2FCD-4C0D-953A-977A993E35CAQ24245342-B759136D-94C4-40E6-996F-AE09A3DA5FAFQ26748617-91642D8A-9E8D-4DE2-B197-4224DACCB2CEQ26765272-95F7757E-912E-41AF-ACDA-877E83C9DB71Q30433078-36D01B5A-18A9-4C33-B2A1-EFDF3D12B2BDQ31036400-3678B21A-930F-4970-B507-7F05E933322FQ31521286-377FB850-47E6-40DA-957F-B2F4EC86D3E2Q32026613-37367B45-92BC-4141-9A0D-C89ED6EEB6F7Q33288913-335EFC09-B625-4B71-BF75-0E4C2B6964B4Q33354600-4D1A4B9A-906C-41DB-AF87-8F38EFB7B58AQ33434046-F01D00C7-B346-40B7-957B-1C5C112E0704Q33470217-26583B01-CFB9-4E41-B20D-2AA616D8A8B4Q33470528-8E8B0944-BD01-4152-85CA-1BF134D568CAQ33586880-AF9295C1-8013-4CD0-A091-C3E923AA497AQ33624179-E3DF493D-7342-4CA2-A3E9-328B02DF4F9FQ33661852-74FB0823-45AB-4508-9CBC-4B8DB93D3905Q33667183-D91719D9-B8C1-4AD8-BB53-E9F3781904CDQ33693294-DA4806C3-9E28-4104-B626-860F55695C60Q33735218-70A98840-2938-48A1-8F46-78E9C37B3911Q33818667-7EB36D92-BD90-4C49-A70F-9347965163DAQ34030234-57954563-5354-49EE-B38A-5D9E06D4B434Q34070408-ACB3DFA1-8C0F-48DC-BC86-F7BD299EAA06Q34078750-DE5811EA-284C-4DEE-A1CD-532FCCA72487Q34345704-AF2AF297-6407-4B55-9D12-C2FF19BF8046Q34473834-81545B12-C5D1-4D16-9809-10D477B0DE87Q34481528-B2A18AD3-9774-4728-AB47-4388EBE55EE1Q34626602-88C7F970-7D43-4479-8816-00EF3F3DD957Q34649076-37766213-ADB6-4397-9BA1-A96DAF3083B9Q34650033-7AB6CF89-0C3F-47B5-844F-2E096F8AE239Q34699846-CC4FB34B-8CE6-42DF-8920-53F49DBD2911Q34699859-49213DC3-483E-4839-BD88-05B601E613E9Q34722737-A7C0EDE0-4B8F-43F1-B14A-42AE910A393DQ34786704-8C81A4A6-59D1-4981-AEB9-9ED564D1A6AEQ34994672-D3F6FDF1-96ED-4938-B7ED-52821327B31EQ35043039-B6FD9CA6-E8D3-41D9-984A-90355808549BQ35071310-C8035BC7-BFC1-400D-847D-4A0CA297224AQ35086847-4F2B001A-308B-4EF0-9D16-B5AF0796E2A5Q35087100-25C3E0B8-4EA2-4B9F-ACCF-CD30392A5042Q35094684-586B5301-8EAC-49D6-A354-509FD58FD6B3Q35200499-B98FB339-5878-47C4-A6D9-7BD2012EF9AE
P2860
Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh
1999年學術文章
@zh-hant
name
Improvement in pain and bowel ...... , a 5-HT3 receptor antagonist.
@en
Improvement in pain and bowel ...... , a 5-HT3 receptor antagonist.
@nl
type
label
Improvement in pain and bowel ...... , a 5-HT3 receptor antagonist.
@en
Improvement in pain and bowel ...... , a 5-HT3 receptor antagonist.
@nl
prefLabel
Improvement in pain and bowel ...... , a 5-HT3 receptor antagonist.
@en
Improvement in pain and bowel ...... , a 5-HT3 receptor antagonist.
@nl
P2093
P2860
P1476
Improvement in pain and bowel ...... , a 5-HT3 receptor antagonist.
@en
P2093
A R Northcutt
A W Mangel
D A Drossman
D McSorley
M Camilleri
P2860
P304
P356
10.1046/J.1365-2036.1999.00610.X
P407
P577
1999-09-01T00:00:00Z